论文部分内容阅读
中性粒细胞抑制因子 (NIF )是整合素LAF 1和Mac 1的配体。作为 β2 整合素的拮抗剂 ,与ICAM 1、ICAM 2竞争性地和LAF 1及Mac 1结合 ,抑制中性粒细胞与内皮细胞的粘附和聚集 ,阻止白细胞的渗透和浸润。因此 ,NIF能用于治疗各种出现白细胞浸润和活化的临床疾病及组织损伤 ,包括休克、中风、急性和慢性同种异体移植排斥反应、血管炎、脓毒症、风湿性关节炎、炎性皮肤病、肠炎、伴随心肌梗塞的局部缺血再灌注损伤和成人呼吸窘迫综合征等。NIF作为一种新的抗炎药 ,具有广阔的应用前景。
Neutrophil Inhibitors (NIFs) are ligands for the integrins LAF 1 and Mac 1. As an antagonist of β2 integrin, it binds ICAM1 and ICAM2 competitively with LAF1 and Mac1 to inhibit the adhesion and aggregation of neutrophils and endothelial cells and prevent the infiltration and infiltration of leukocytes. Therefore, NIF can be used to treat a variety of clinical conditions and tissue damage that involve leukocyte infiltration and activation, including shock, stroke, acute and chronic allograft rejection, vasculitis, sepsis, rheumatoid arthritis, inflammatory Dermatology, enteritis, ischemia-reperfusion injury with myocardial infarction and adult respiratory distress syndrome. As a new anti-inflammatory drug, NIF has broad application prospects.